USA flag logo/image

An Official Website of the United States Government

Diverse mix of Human MoAbs to treat Anthrax exposure

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65932
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
AI052901
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AVANIR PHARMACEUTICALS
AVANIR PHARMACEUTICALS 11388 SORRENTO VALLEY RD, STE 200 SAN DIEGO, CA 92121 0134
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Diverse mix of Human MoAbs to treat Anthrax exposure
Agency: HHS
Contract: 1R43AI052901-01A1
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by the applicant): The long-term goal of this proposal (phase I and II) is the development of a human monoclonal antibody-based preparation for use in treating B. anthracis (anthrax) exposure or for use prophylactically. This preparation would most likely be composed of multiple, different monoclonal antibodies. Such a preparation would fill a significant void in the arsenal of reagents available to treat this biowarfare threat. Phase I specific aims are: 1) Evaluate the human antibody response of peripheral blood leukocytes from AVA vaccinated donors in the human lymphocyte engrafted SCID mouse (hu-PBL-SCID system). Immunogens will include a) recombinant Protective Antigen (PA), b) the active fragment of PA, c) Lethal Factor (LF), and (optionally) d) the Lethal Toxin formed from PA+LF. Antigen specific serum human antibodies will be detected by 'ELISA, and neutralizing antibody levels will be measured using the murine macrophage cell line RAW. 2) Evaluate Lethal Toxin treatment as an in vivo approach to select mice making neutralizing antibodies. 3) Generate, from selected animals, an initial series of human monoclonal antibodies specific for PA, and possibly LF. These will be characterized for neutralizing activity, and using BIACORE, affinity and epitope grouping. The main goal of the phase II proposal will be the configuration of at least one combination of human monoclonals which could be evaluated in vivo for the ability to protect and/or rescue from B. anthracis challenge. The phase II SBIR program may require the generation of a larger panel of antibodies, based on the success of phase I.

Principal Investigator:

Phillip R. Morrow
8586225257
PMORROW@AVANIR.COM

Business Contact:

David Hansen
8586225215
DHANSEN@AVANIR.COM
Small Business Information at Submission:

AVANIR PHARMACEUTICALS
AVANIR PHARMACEUTICALS 11388 SORRENTO VALLEY RD, STE 200 SAN DIEGO, CA 92121

EIN/Tax ID: 330314804
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No